Cancer-related bone pain remains a clinical challenge, particularly in patients with metastatic disease who have failed conventional pharmacologic therapies. Suzetrigine, a selective NaV1.8 sodium channel inhibitor, is a novel non-opioid analgesic with potenti... ...

请注册登录后继续浏览